Novartis' Chinese vaccine presence boosted by acquisition
This article was originally published in Scrip
Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan. The acquisition was first proposed in 2009 at a purchase price of Yuan850 million (around $130 million), but required Chinese regulatory and government approvals.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.